watch
Johnson & Johnson

Johnson & Johnson

Sector: Pharmaceutical Preparations Region: NJ, United States


: | XETRA: JNJ | Mexican Stock Exchange: JNJ | New York Stock Exchange: JNJ


Similar to: ViroPharma, Inc., Wuxi PharmaTech Inc., BioGaia AB

Johnson & Johnson operates as an investment holding company with interests in health care products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. The company, through its subsidiaries operates in three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. The baby care franchise includes the JOHNSON'S Baby line of products. Major brands in the skin care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; DABAO; and VENDÔME product lines. Brands in the oral care franchise include the LISTERINE and REMBRANDT oral care lines, as well as REACH interdental products. The wound care franchise includes BAND-AID brand adhesive bandages and NEOSPORIN First Aid products. Major brands in the women's health franchise are CAREFREE pantiliners; o.b. tampons and STAYFREE sanitary protection products. The principal nutritional line is SPLENDA No Calorie Sweetener. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller. The Pharmaceutical segment includes products in the anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis and vaccines areas. The products in this segment include REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis; VELCADE (bortezomib), a treatment for multiple myeloma; ZYTIGA (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer; PREZISTA (darunavir), INTELENCE (etravirine) and EDURANT (rilpivirine), treatments for HIV/AIDS; INCIVO (telaprevir), for the treatment of hepatitis C; NUCYNTA ER (tapentadol) extended release tablets, a treatment for moderate to severe chronic pain in adults and neuropathic pain associated with diabetic peripheral neuropathy in adults; INVEGA SUSTENNA (paliperidone palmitate), for the acute and maintenance treatment of schizophrenia in adults; INVEGA (paliperidone) extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; RISPERDAL CONSTA (risperidone), a treatment for the management of Bipolar I Disorder and schizophrenia; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of thrombosis following total hip or knee replacement surgery, for the prevention of stroke in patients with atrial fibrillation, for the treatment of pulmonary embolism (PE) or deep vein thrombosis (DVT) or to reduce the risk of recurrence of DVT or PE following an initial six months of treatment for acute venous thromboembolism; PROCRIT (epoetin alfa, sold as EPREX), to stimulate red blood cell production; LEVAQUIN (levofloxacin) for the treatment of bacterial infections; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/ (fentanyl transdermal system) CII, sold as DUROGESIC, a treatment for chronic pain that offers a novel delivery system. The Medical Devices and Diagnostics segment produces a range of products used primarily by health care professionals in the fields of cardiovascular disease; orthopaedic and neurological; blood glucose monitoring and insulin delivery; general surgery; biosurgical, and energy; professional diagnostic; infection prevention products; and disposable contact lenses. Johnson & Johnson was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Investor Calendar

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

The Johnson & Johnson Museum

We are reinvesting in our history by developing a cutting-edge virtual museum, while also renovating the Johnson & Johnson Museum, located on our campus in New Brunswick, New Jersey.

Johnson & Johnson video

The Johnson & Johnson Museum

Johnson & Johnson video

A History of Leadership at Johnson & Johnson

Johnson & Johnson video

Highlights from the J&J Annual Meeting of Shareholders

Executives

Alex Gorsky, Chief Executive Officer
Mr. Gorsky began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica Inc. in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, Mr. Gorsky was appointed President of Janssen Pharmaceutical Inc., and in 2003, he was named Company Group Chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson & Johnson in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company's pharmaceuticals business in North America. Mr. Gorsky returned to Johnson & Johnson in 2008 as Company Group Chairman for Ethicon. In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and member of the Executive Committee. In September 2009, he was appointed Worldwide Chairman of the Medical Devices and Diagnostics Group. Mr. Gorsky became Vice Chairman of the Executive Committee in January 2011. On April 26, 2012, he assumed his current position.
Mr. Gorsky represents Johnson & Johnson on the board of AdvaMed, the U.S. trade association for the medical device and diagnostics industry. A longtime advocate of diversity and inclusion, Mr. Gorsky was named the 2009 Mentor of the Year by the Healthcare Businesswomen's Association, an organization he has been involved with for many years. He is the Executive Sponsor of two Johnson & Johnson affinity groups, the Women's Leadership Initiative and the Veteran's Leadership Council.
Mr. Gorsky holds a Bachelor of Science degree from the U.S. Military Academy at West Point, NY, and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Mr. Gorsky earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.
Dominic J. Caruso, Chief Financial Officer
Dominic J. Caruso is Vice President, Finance and Chief Financial Officer of Johnson & Johnson. Mr. Caruso serves as a member of the Executive Committee, the Management Compensation Committee and Pension and Benefits Committee, and has responsibility for financial and investor relations activities.
Mr. Caruso joined Johnson & Johnson in October 1999 as Chief Financial Officer for Centocor, Inc., with the completion of the merger of Centocor and Johnson & Johnson. In 2001, Mr. Caruso was named Vice President of Finance for Ortho-McNeil Pharmaceutical, Inc. and a member of its management board. He was named Vice President, Group Finance for Johnson & Johnson's Medical Devices and Diagnostics Group, and a member of the Medical Devices and Diagnostics Group Operating Committee in May 2003. Mr. Caruso assumed responsibility for the Company's Group Finance organization in December 2005, the position he held until being named to his present position in January 2007.
Prior to joining Johnson & Johnson, he had been with Centocor since 1985 with responsibilities for finance, information management, investor relations, procurement and facility services. He also served as General Manager of Centocor's Diagnostic Division. Prior to joining Centocor, he had varied industry experiences with the audit and tax services firm, KPMG.
Mr. Caruso serves as a director of the Board of Trustees of The Children's Hospital of Philadelphia and the Delaware Valley Chapter of the Cystic Fibrosis Foundation.
Mr. Caruso graduated from Drexel University with a B.S. degree in business administration
Peter M. Fasolo, Ph.D. , Vice President, Global Human Resources
Peter M. Fasolo is the Vice President, Global Human Resources, responsible for the global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company. Mr. Fasolo is a member of the Executive Committee, Management Compensation Committee, and Chairman of the Pension and Benefits Committee.
Mr. Fasolo first joined Johnson & Johnson in 2004 as Worldwide Vice President, Human Resources for Cordis Corporation, where he worked extensively on the merger and acquisition strategy for the Cordis cardiovascular business. He was then named Vice President, Global Talent Management, with responsibility for executive assessment and development, working closely with senior leadership to determine the talent needs of the business to execute the corporate strategy. Mr. Fasolo left Johnson & Johnson in 2007 to join Kohlberg Kravis Roberts & Co. (KKR) as Chief Talent Officer for the portfolio companies owned by the firm. He returned to Johnson & Johnson in September 2010, and was appointed Vice President, Global Human Resources in October 2010. Mr. Fasolo was appointed as a member of the Executive Committee in January 2011.
Mr. Fasolo has more than 15 years experience in consulting in the healthcare and consumer industries, having spent 13 years with Bristol-Myers Squibb in executive level, human resource roles in the pharmaceutical, medical devices and consumer segments.
Mr. Fasolo earned a Ph.D. in Organizational Behavior from the University of Delaware, an M.A. in Industrial Psychology from Fairleigh Dickinson University and a B.A. in Psychology from Providence College.

News & Analysis

You may also be interested in: